Savara Inc. $SVRA Position Reduced by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. reduced its shares in Savara Inc. by 2.3%, selling 190,723 shares during the first quarter, while still holding about 8.1 million shares valued at $22.5 million.
• Multiple investment firms have increased their positions in Savara, with Millennium Management LLC boosting their holdings by 71.8% in the last quarter.
• Analysts have mixed views on Savara's stock, with a consensus rating of "Moderate Buy" and a price target averaging $6.17, despite varying opinions on future price levels.

Vanguard Group Inc. lowered its holdings in Savara Inc. (NASDAQ:SVRA - Free Report) by 2.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,119,247 shares of the company's stock after selling 190,723 shares during the period. Vanguard Group Inc. owned approximately 4.70% of Savara worth $22,490,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in SVRA. Wells Fargo & Company MN increased its position in shares of Savara by 42.9% in the fourth quarter. Wells Fargo & Company MN now owns 59,277 shares of the company's stock worth $182,000 after acquiring an additional 17,786 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Savara in the fourth quarter worth $798,000. Barclays PLC increased its position in shares of Savara by 2.5% in the fourth quarter. Barclays PLC now owns 236,705 shares of the company's stock worth $728,000 after acquiring an additional 5,700 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Savara in the fourth quarter worth $34,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Savara by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after acquiring an additional 5,450 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Insider Buying and Selling

In related news, Director Richard J. Hawkins acquired 48,225 shares of Savara stock in a transaction on Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director directly owned 115,466 shares of the company's stock, valued at $235,550.64. The trade was a 71.72% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.33% of the stock is owned by company insiders.

Savara Stock Up 3.3%

SVRA traded up $0.11 during trading hours on Wednesday, reaching $3.42. 4,373,965 shares of the stock traded hands, compared to its average volume of 1,329,670. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $4.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The company has a market cap of $591.10 million, a price-to-earnings ratio of -6.84 and a beta of 0.56. The firm's fifty day simple moving average is $2.66 and its two-hundred day simple moving average is $2.70.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). As a group, analysts forecast that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. HC Wainwright increased their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday. Guggenheim reaffirmed a "buy" rating and set a $8.00 price target (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Oppenheimer raised their price target on shares of Savara from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, August 15th. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Wednesday, May 28th. Finally, Wells Fargo & Company lowered their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.67.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.